A plasma-bubble reactor, reactor system and method for producing hydrogen peroxide (H2O2), one or more hydrocarbon(s), and syngas is disclosed. The reactor comprises a vessel configured to hold a liquid; and a plasma generating means, in association with the vessel, configured to receive an input feed comprising carbon dioxide (CO2) gas and generate a plasma from the CO2 gas to produce an activated CO2 gas encapsulated within a plurality of bubbles formed in the liquid, wherein the activated CO2 gas reacts with water (H2O) at a plasma-liquid interface formed between the bubbles and the surrounding liquid to produce hydrogen peroxide (H2O2), one or more hydrocarbon(s) and syngas.
C25B 11/077 - Electrodes formed of electrocatalysts on a substrate or carrier characterised by the electrocatalysts material consisting of a single catalytic element or catalytic compound the compound being a non-noble metal oxide
C25B 15/08 - Supplying or removing reactants or electrolytesRegeneration of electrolytes
CENTENARY INSTITUTE OF CANCER MEDICINE AND CELL BIOLOGY (Australia)
UNIVERSITY OF SYDNEY (Australia)
Inventor
Hogg, Philip
Ho Shon, Ivan
Abstract
The disclosure relates to a radiolabelled conjugate of a trivalent arsenical compound, the use of such a radiolabelled conjugate in the diagnosis and treatment of conditions associated with cell death, such as neoplastic conditions, and processes for preparing such a radiolabelled conjugate.
The present disclosure relates to a sensing material which may be applied in a chemiresistive carbon dioxide sensor, the sensing material comprising a nitrogen-containing polymer, and an amine having a molecular weight of less than about 1000 g/mol.
C08F 220/36 - Esters containing nitrogen containing oxygen in addition to the carboxy oxygen
C08F 220/60 - Amides containing nitrogen in addition to the carbonamido nitrogen
G01N 27/04 - Investigating or analysing materials by the use of electric, electrochemical, or magnetic means by investigating impedance by investigating resistance
G01N 27/12 - Investigating or analysing materials by the use of electric, electrochemical, or magnetic means by investigating impedance by investigating resistance of a solid body in dependence upon absorption of a fluidInvestigating or analysing materials by the use of electric, electrochemical, or magnetic means by investigating impedance by investigating resistance of a solid body in dependence upon reaction with a fluid
G01N 33/00 - Investigating or analysing materials by specific methods not covered by groups
The present disclosure relates to systems, vectors, and compositions for gene editing via the site-specific insertion of gene sequences, and methods of use thereof. In particular, the present disclosure relates to gene editing systems derived from insertion sequences and associated transposases.
Microfluidic devices and methods for their fabrication are described. The microfluidic devices comprise one or more enclosed microfluidic channels, wherein the internal surfaces of the microfluidic channels are modified through plasma activation and/or atmospheric pressure plasma jet treatment. The treated surfaces of the microfluidic devices can covalently attach or immobilise biomolecules or cells which is useful for applications such as an organ-on-a-chip device, lab-on-a-chip device, a separation device, a cell/biomarker-capture device, a diagnostic device, a synthesis device, or a sensor device.
Substrates modified with plasma-activated coatings are provided, as are processes for their preparation. The coated substrates may possess high transparency and are radical rich, enabling covalent attachment of biomolecules, for example proteins.
C03C 17/34 - Surface treatment of glass, e.g. of devitrified glass, not in the form of fibres or filaments, by coating with at least two coatings having different compositions
C12N 5/00 - Undifferentiated human, animal or plant cells, e.g. cell linesTissuesCultivation or maintenance thereofCulture media therefor
The present disclosure relates to a portable communication device (301). The portable communication device comprises a controller (302) configured to receive (210) first and second images from one or more cameras (340) and to transmit images to a video display (314). The portable communication device also comprises an electroencephalogram (EEG) device (350) configured to capture EEG signals of a brain of a user, wherein the controller is configured to receive the EEG signals from the EEG device. The controller is configured for detecting (220) an object on the received first images, displaying (230) a word associated with the detected object on the video display, determining (510) a gaze point of one or more eyes of the user based on second images of cameras, wherein the second images relate to the one or more eyes of the user, verifying (520) the determined gaze point based on the EEG signals, and determining (540) a word or a function selected on the video display based on the gaze point.
The present invention provides a multi-lumen catheter device for delivery of microwave energy to a target region of tissue by way of a microwave radiation antenna electrically connectible via a microwave feedline to an electrical microwave system. The device includes an antenna-receiving chamber for accommodating the microwave radiation antenna, one or more orifices providing fluid connection between the antenna- receiving chamber and the outside of the device, a primary lumen configured to accommodate the microwave feedline and a first electrode connected to an electrical sensing system and to provide fluid flow to the antenna-receiving chamber, one or more substantially toroidal internal bores, each providing a flow gallery in fluid connection to the outside of the device by way of a first plurality of spaced orifices, and one or more secondary lumens separate to the primary lumen, each secondary lumen configured to accommodate a second electrode connected to the electrical sensing system, each secondary lumen in fluid connection with a flow gallery. Fluid flow along the secondary lumen(s) exits the device through the first plurality of spaced orifices via a flow gallery, and the electrical circuit created between the respective electrodes includes an ionic conductivity bridge between the second electrode(s) and the plurality of spaced orifices, which thus act as a saline ring electrode for sensing tissue response or for applying electrical signals for other purposes.
A61B 18/18 - Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by applying electromagnetic radiation, e.g. microwaves
A61B 5/28 - Bioelectric electrodes therefor specially adapted for particular uses for electrocardiography [ECG]
A61B 5/308 - Input circuits therefor specially adapted for particular uses for electrocardiography [ECG]
A61B 5/318 - Heart-related electrical modalities, e.g. electrocardiography [ECG]
A61B 18/00 - Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
The present invention relates to a particle analyser. In particular, the present invention relates to a device and a method for monitoring a dynamic profile of particles including deposition, and/or diffusion and/or dissolution rates of the particles.
The present invention relates to a device for aerosol characterisation. In particular, the present invention relates to a device and a method for providing dynamic measurement of an aerosol travelling in a mouth-throat model, a mouth-throat model comprising the device and an aerosol characterisation system comprising the device.
An optical sensor for detecting a chemical species in a sample, the optical sensor comprising a single mode fibre having a fibre Bragg grating, wherein the fibre Bragg grating has a refractive index profile, the optical sensor arranged to provide an output optical signal based on a positive detection of the chemical species in the sample, wherein the sample, upon illumination, emits a sample optical signal having an optical frequency signature comprising a plurality of spectral lines that are associated with the chemical species, wherein the refractive index profile is associated with the optical frequency signature, and the fibre Bragg grating is arranged to be modulated to generate the output optical signal.
G01N 21/3504 - Investigating relative effect of material at wavelengths characteristic of specific elements or molecules, e.g. atomic absorption spectrometry using infrared light for analysing gases, e.g. multi-gas analysis
Plasma enhanced chemical vapour deposited films are described. Methods of producing said films and their uses are also described. The films comprise one or more first regions and one or more second regions, said first regions being more electrically conductive than said second regions. Biomolecules or cells can be covalently attached or immobilised onto the films and the films can be used for the individual or simultaneous electrical and optical analysis of said biomolecules or cells.
C23C 16/50 - Chemical coating by decomposition of gaseous compounds, without leaving reaction products of surface material in the coating, i.e. chemical vapour deposition [CVD] processes characterised by the method of coating using electric discharges
C12N 5/00 - Undifferentiated human, animal or plant cells, e.g. cell linesTissuesCultivation or maintenance thereofCulture media therefor
C12N 11/00 - Carrier-bound or immobilised enzymesCarrier-bound or immobilised microbial cellsPreparation thereof
C23C 16/52 - Controlling or regulating the coating process
G01N 33/483 - Physical analysis of biological material
The invention relates to compounds of formula (I), optionally radiolabelled with a radionuclide, and pharmaceutically acceptable salts, solvates, tautomers, N-oxides, stereoisomers and/or polymorphs thereof. Also disclosed are methods of using the compounds of formula (I) for detecting translocator protein (18 kDa) (TSPO). Further disclosed are methods of using the compounds of formula (I) for diagnosing and/or treating a disease, disorder or condition associated with TSPO.
A61K 31/4162 - 1,2-Diazoles condensed with heterocyclic ring systems
A61K 31/435 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
A61K 31/4439 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
A clip (1) for holding a microfluidic device (50) with a generally planar bottom surface (51) and generally planar top surface (52), includes a base (20) with a supporting surface (21) to support the bottom surface (51) of the microfluidic device (50); a cover (30) to hold the microfluidic device (50) on the supporting surface (21) of the base (20); a hinge (40) connecting the cover (30) to the base (20) for rotation of the cover (30) about a hinge axis (41); a pressure plate (31) mounted to the cover (30) for relative rotation about a rotation axis (32) extending parallel to the hinge axis (41), the pressure plate (31) has an abutment surface (33) for engagement with the top surface (52) of the microfluidic device (50); and a clamp mechanism (61) to releasably secure the cover (30) to the base (20) to compressively hold the microfluidic device (50) between the supporting surface (21) and the abutment surface (33). The rotatable pressure plate (31) pressing flush onto the top surface (52) allows the compression applied by the clamp (61) across the microfluidic device (50) to be more uniform. (Fig. 4 to accompany Abstract)
CENTENARY INSTITUTE OF CANCER MEDICINE AND CELL BIOLOGY (Australia)
THE UNIVERSITY OF SYDNEY (Australia)
Inventor
Gamble, Jennifer Ruth
Vadas, Mathew Alexander
Ting, Ka Ka
Abstract
The present disclosure relates generally to the use of agents, such as oligonucleotides, to improve, increase, restore or retain the integrity of the blood brain barrier; and/or to reduce the deposition or accumulation of and/or promote the clearance of, amyloid-β. The disclosure also related to agents, such as oligonucleotides, that increase, promote or restore the level or amount of VE-cadherin in a cell, and are thus useful in the methods of the present disclosure. The present disclosure also relates to the use of such agents to treat diseases and conditions associated with damage to the blood brain barrier, including diseases and conditions associated with neuroinflammation and neurodegeneration, as well as diseases and conditions associated with amyloid-β deposition, including Alzheimer's disease (AD), Cerebral amyloid angiopathy (CAA), Lewy body dementia (LBD) and traumatic brain injury (TBI).
C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
A61K 31/7105 - Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
A61K 31/712 - Nucleic acids or oligonucleotides having modified sugars, i.e. other than ribose or 2'-deoxyribose
A61P 9/10 - Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
B01D 53/32 - Separation of gases or vapoursRecovering vapours of volatile solvents from gasesChemical or biological purification of waste gases, e.g. engine exhaust gases, smoke, fumes, flue gases or aerosols by electrical effects other than those provided for in group
B01D 53/96 - Regeneration, reactivation or recycling of reactants
C25B 9/19 - Cells comprising dimensionally-stable non-movable electrodesAssemblies of constructional parts thereof with diaphragms
A system and method of detecting presence of arrythmia in an electrocardiogram (ECG) signal. The method comprises steps of applying a decomposition algorithm to one or more portions of the ECG signal, each portion corresponding to at least one heartbeat. The method also comprises, for each portion, selecting at least one output of the decomposition algorithm; providing the selected at least one output to a first trained convolutional neural network (CNN) arrangement, the first CNN arrangement generating coefficients of a predetermined size; and inputting the coefficients of the predetermined size to a second trained CNN arrangement, the second CNN arrangement trained to output a classification of whether arrythmia is present in the portion of the ECG.
G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
A system and method for measuring acceleration. The system comprises a diamond having a nitrogen-vacancy centre configured to emit fluorescence under optical illumination in presence of a radio frequency field tuned to a resonant frequency of the nitrogen-vacancy centre, and a magnet, wherein a distance between the magnet and the diamond varies in response to acceleration of the system, the change in distance altering a magnetic field experienced by the diamond. The system also comprises an optical sensor, the optical sensor configured to sense variation in fluorescence emitted by the diamond in response to the altered magnetic field for measuring acceleration.
G01P 15/093 - Measuring accelerationMeasuring decelerationMeasuring shock, i.e. sudden change of acceleration by making use of inertia forces with conversion into electric or magnetic values by photoelectric pick-up
22.
SYSTEM AND METHOD FOR PUMPING A FLUID THROUGH A TARGET UNIT
The invention provides a system for pumping a fluid through a target unit, comprising a source of compressed gas, a gas circuit connected to said source of compressed gas and including gas flow control apparatus, a first connection and a second connection for connecting to, respectively, afferent and efferent ends of the target unit, a fluid flow circuit in fluid communication with said first and second connections, the fluid flow circuit including fluid control apparatus and a first and second fluid reservoir, wherein the gas flow control apparatus provides coordinated delivery and release of compressed gas to dynamically control fluid level in each of said first and second fluid reservoirs in order to provide, by way of operation of the fluid control apparatus in the fluid flow circuit, continuous fluid flow through the target unit in a single direction in accordance with a predetermined flow profile.
The present disclosure relates to methods of forming a graft of a second polymer on the surface of a material comprised of a first polymer, and methods of preventing the deterioration of said graft.
A61L 33/00 - Antithrombogenic treatment of surgical articles, e.g. sutures, catheters, prostheses, or of articles for the manipulation or conditioning of bloodMaterials for such treatment
C08F 259/04 - Macromolecular compounds obtained by polymerising monomers on to polymers of halogen containing monomers as defined in group on to polymers containing chlorine on to polymers of vinyl chloride
C08F 259/08 - Macromolecular compounds obtained by polymerising monomers on to polymers of halogen containing monomers as defined in group on to polymers containing fluorine
C08F 265/04 - Macromolecular compounds obtained by polymerising monomers on to polymers of unsaturated monocarboxylic acids or derivatives thereof as defined in group on to polymers of esters
C08F 283/00 - Macromolecular compounds obtained by polymerising monomers on to polymers provided for in subclass
C08F 283/01 - Macromolecular compounds obtained by polymerising monomers on to polymers provided for in subclass on to unsaturated polyesters
C08F 285/00 - Macromolecular compounds obtained by polymerising monomers on to preformed graft polymers
THE COUNCIL OF THE QUEENSLAND INSTITUTE OF MEDICAL RESEARCH (Australia)
Inventor
Munoz, Lenka
Kassiou, Michael
Joun, George
Chen, Brianna
Abstract
This disclosure relates to combinations of tubulin polymerisation inhibitors and cholesterol homeostasis disrupting agents that are useful in the treatment of proliferative diseases, such as cancer. Preferred combinations are shown as effective against various cancer cell types, including brain cancers such as glioblastomas.
A61K 31/137 - Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine
A61K 31/167 - Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen atom of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
A61K 31/195 - Carboxylic acids, e.g. valproic acid having an amino group
A61K 31/416 - 1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
A61K 31/499 - Spiro-condensed pyrazines or piperazines
A61K 31/575 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
A61K 47/20 - Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
A61K 47/26 - Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharidesDerivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
A method for determining moisture content of soil within a measurement zone of a field includes transmitting and/or receiving radio frequency signals between a plurality of spaced apart nodes and receiving, by a controller, signal data about the intensity of radio frequency signals transmitted and/or received from each of the plurality of spaced apart radio nodes. The method transmits, by the controller, the signal data about the intensity or other characteristic of radio frequency signals to a server and the relative signal strength of the radio frequency signals transmitted between each of the plurality of spaced apart nodes. The moisture content of soil for each location between each of the plurality of spaced apart nodes within the measurement zone is then determined.
G01S 5/02 - Position-fixing by co-ordinating two or more direction or position-line determinationsPosition-fixing by co-ordinating two or more distance determinations using radio waves
G01V 3/12 - Electric or magnetic prospecting or detectingMeasuring magnetic field characteristics of the earth, e.g. declination or deviation operating with electromagnetic waves
G01V 9/02 - Determining existence or flow of underground water
The object of the present invention is to provide a microsampling device that allows analysis of proteins in a biological sample, such as a whole blood sample, and provide methods of using the same.
A system and method of measuring blood pressure behaviour of a subject. One method comprises extracting at least one waveform from a sound recording of operation of the subject's heart, each waveform representing sounds generated by operation of the subject's heart; averaging each of the extracted waveforms over a predetermined interval; and extracting features of the each of the averaged waveforms based on shape of the averaged waveforms. Other methods extract at least one element as the feature, the element(s) being a ratio of of form Xαβ_YδΦ, where each of X and Y is a peak or notch in any of the deriving waveform shapes, each of α and δ identifies one of the plurality of determined waveform shapes and each of β and Φ, relates to the allocated number of the corresponding peak or notch. The method further comprises providing the extracted features to a model trained for the subject to determine a measurement of blood pressure behaviour of the subject.
The invention relates to a method for use in assessing eye contact of a subject participant in a social interaction scenario between participants. The method involves using camera apparatus to capture video images of the subject participant as a recorded image stream, processing the captured video images to provide data representing spatial and temporal features of the recorded image stream, and using a computer processing module to apply an action recognition algorithm to the data to predict occurrences of eye contact of the subject participant. The invention has particular application in evaluation of children, to assess development of social skills in a simulated, real-life interaction scenario such as a free play task guided by a facilitator in a way that prompts eye contact by the subject participant child.
A61B 5/16 - Devices for psychotechnicsTesting reaction times
A61B 3/113 - Objective types, i.e. instruments for examining the eyes independent of the patients perceptions or reactions for determining or recording eye movement
A61B 3/14 - Arrangements specially adapted for eye photography
A61B 5/00 - Measuring for diagnostic purposes Identification of persons
A method, system and computer readable storage medium for controlling a state of accounts. In one aspect, the method uses a data structure storing a plurality of transactions representing the state of accounts. The method comprises receiving a request by a node of a plurality of nodes to create a transaction and determining a type of the transaction based on the request. The determined type of the transaction is used to determine whether to add the transaction to a data structure storing a plurality of transactions representing a state of accounts. In response to determining that the transaction is to be added to the data structure, storing the transaction in the data structure based on the determined type to control the state of accounts. The transaction may by stored in the data structure using a link corresponding to the determined type. The determined type corresponds to a type from a plurality of types comprising a retractable transaction and a non-retractable transaction.
A61K 31/166 - Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon atom of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
A61P 1/00 - Drugs for disorders of the alimentary tract or the digestive system
A61P 9/10 - Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
A61P 19/02 - Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
A61P 25/02 - Drugs for disorders of the nervous system for peripheral neuropathies
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
C07C 237/30 - Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton having the nitrogen atom of the carboxamide group bound to hydrogen atoms or to acyclic carbon atoms
A61K 31/166 - Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon atom of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
A61P 9/04 - Inotropic agents, i.e. stimulants of cardiac contractionDrugs for heart failure
C07C 209/50 - Preparation of compounds containing amino groups bound to a carbon skeleton by reduction of carboxylic acids or esters thereof in presence of ammonia or amines, or by reduction of nitriles, carboxylic acid amides, imines or imino-ethers by reduction of carboxylic acid amides
C07C 231/02 - Preparation of carboxylic acid amides from carboxylic acids or from esters, anhydrides, or halides thereof by reaction with ammonia or amines
C07C 231/12 - Preparation of carboxylic acid amides by reactions not involving the formation of carboxamide groups
The Westmead Institute for Medical Research (Australia)
Western Sydney Local Health District (Australia)
Inventor
Duong, Thi Thu Hien
Iredell, Jonathan
Huang, Huiping
Abstract
The present invention relates to phage-drug conjugates and methods for preparing phage-drug conjugates. The present invention also relates to methods of using the phage-drug conjugates.
A61K 47/69 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
A61K 47/60 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
This disclosure relates to compounds that include a first chelating ligand selective for 89Zr linked by a linker group to a second chelating ligand selective for a radionuclide other than 89Zr. Also disclosed are complexes, pharmaceutical agents and compositions comprising the compounds. The disclosure also provides methods for the use and production of the compounds, complexes, pharmaceutical agents and compositions.
THE WESTMEAD INSTITUTE FOR MEDICAL RESEARCH (Australia)
WESTERN SYDNEY LOCAL HEALTH DISTRICT (Australia)
Inventor
Kizana, Eddy
Kok, Cindy
Lisowski, Leszek
Abstract
The present disclosure provides variant AAV capsid polypeptides that, when present in the capsid of an AAV vector, facilitate efficient transduction of cardiac cells, in particular human cardiac cells. Also provided are methods for preparing AAV vectors, in particular vectors that transduce cardiac cells, and in particular AAV vectors for gene therapy uses, in particular those targeting the heart or cardiac cells and tissue.
The present invention relates to a liquid metal battery and a method of exchanging energy with an external device. In particular, the present invention relates to a liquid metal battery comprising a flow inducer configured to induce a swirl flow.
H01M 50/00 - Constructional details or processes of manufacture of the non-active parts of electrochemical cells other than fuel cells, e.g. hybrid cells
H01M 4/38 - Selection of substances as active materials, active masses, active liquids of elements or alloys
H01M 10/39 - Accumulators not provided for in groups working at high temperature
A method (100) of fabricating a heart valve replacement, the method (100) comprising: obtaining a representation (200) of a native heart valve (202) of a subject; obtaining one or more profiles of the native heart valve (202) from the representation (200) of the native heart valve (202), the one or more profiles defining one or more geometries of the native heart valve (202); deriving one or more mathematical functions from the one or more profiles; generating a model (400) of the heart valve replacement using the one or more mathematical functions; and fabricating the heart valve replacement based on the model (400) of the heart valve replacement.
A wearable blood pressure measuring or monitoring device (100) comprises a housing (110) for receiving a limb (120), a first actuator (130) for applying a load force at a first location (150) of the limb to restrict blood flow (140) and a one or more first sensors (160) for detecting biometric parameter(s) at a second location (190) of the limb. The one or more first sensors (160) detects the biometric parameter(s) when the first actuator (130) applies the load force to determine the blood pressure of the patient. A one or more second sensors (270) detects biometric parameter(s) at the first location (150). An optional second actuator (520) may apply a load force at the second location, so that biometric parameter(s) can be measured at both locations when blood flow is restricted and unrestricted. An associated method and system use a neural network to calculate the blood pressure from the measured data.
A61B 5/022 - Measuring pressure in heart or blood vessels by applying pressure to close blood vessels, e.g. against the skinOphthaldynamometers
A61B 5/00 - Measuring for diagnostic purposes Identification of persons
A61B 5/021 - Measuring pressure in heart or blood vessels
A61B 5/0225 - Measuring pressure in heart or blood vessels by applying pressure to close blood vessels, e.g. against the skinOphthaldynamometers the pressure being controlled by electric signals, e.g. derived from Korotkoff sounds
A61B 5/1455 - Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value using optical sensors, e.g. spectral photometrical oximeters
G06N 3/063 - Physical realisation, i.e. hardware implementation of neural networks, neurons or parts of neurons using electronic means
G16H 50/30 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indicesICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for individual health risk assessment
Chemiresistive polyunsaturated fatty acid (PUFA) sensing devices are described. The devices comprise conductive polymers and at least one first enzyme and at least one second enzyme. Methods of fabricating a PUFA sensing device are also described. The device shows excellent sensitivity towards PUFAs.
C12Q 1/00 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions
C12N 9/08 - Oxidoreductases (1.), e.g. luciferase acting on hydrogen peroxide as acceptor (1.11)
C12N 11/04 - Enzymes or microbial cells immobilised on or in an organic carrier entrapped within the carrier, e.g. gel or hollow fibres
C12N 11/082 - Enzymes or microbial cells immobilised on or in an organic carrier the carrier being a synthetic polymer obtained by reactions only involving carbon-to-carbon unsaturated bonds
C12N 11/084 - Polymers containing vinyl alcohol units
C12N 11/098 - Enzymes or microbial cells immobilised on or in an organic carrier the carrier being a synthetic polymer formed in the presence of the enzymes or microbial cells
C12Q 1/26 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving oxidoreductase
C12Q 1/28 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving oxidoreductase involving peroxidase
G01N 33/92 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving lipids, e.g. cholesterol
The present invention relates to an aqueous coating composition comprising a polymer binder, opacifier particles and polymer fibres having (i) an average diameter of less than 200 nm, and (ii) a composition formed from a block copolymer arranged so as to provide the polymer fibres with a hydrophobic core and a hydrophilic shell structure, wherein the opacifier particles are not vesiculated polymer particles or contained within vesiculated polymer particles.
C08F 293/00 - Macromolecular compounds obtained by polymerisation on to a macromolecule having groups capable of inducing the formation of new polymer chains bound exclusively at one or both ends of the starting macromolecule
The present invention relates to phage-extracellular vesicle (EV) conjugates, wherein the phage is linked with an EV by a linker, wherein the phage and the EV are independently conjugated to the linker by one or more types of cleavable bond, and methods for preparing phage-EV conjugates. The present invention also relates to methods of using the phage-EV conjugates, in particular for promoting tissue repair in an individual having damaged tissue such as associated with a bacterial infection.
A61K 47/58 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. poly[meth]acrylate, polyacrylamide, polystyrene, polyvinylpyrrolidone, polyvinylalcohol or polystyrene sulfonic acid resin
A61P 17/02 - Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
C08F 293/00 - Macromolecular compounds obtained by polymerisation on to a macromolecule having groups capable of inducing the formation of new polymer chains bound exclusively at one or both ends of the starting macromolecule
The present invention is concerned with a wireless device comprising: a communication processor; WiFi hardware operable to access a WiFi communication channel; and a computer-readable medium storing instructions, which when executed by the communications processor, cause the communication processor to: execute, in a MAC layer of a communication protocol stack, a channel-access scheduler that controls the WiFi hardware to access the WiFi communication channel by way of a TDMA channel-access method.
A portable detection system for detecting a pathogen or virus, the portable detection system comprising: at least one light source for generating an input optical signal; at least one optical sensor comprising at least one optical fibre having at least one tapered sensing region with at least one coating that reacts with a pathogen being detected, wherein the optical sensor is arranged to receive the input optical signal, communicate the input optical signal through the tapered sensing region and communicate an output optical signal from the tapered sensing region; at least one photodetector for detecting power intensity of the output optical signal, wherein the photodetector is arranged to generate an output signal based on a change in power intensity of the output power at a resonant wavelength that corresponds with the pathogen; and at least one microcontroller for controlling the light source, optical sensor and photodetector; wherein the portable detection system is arranged to cause an output to be generated based on the output signal, wherein the output is associated with the pathogen being detected.
G01N 21/77 - Systems in which material is subjected to a chemical reaction, the progress or the result of the reaction being investigated by observing the effect on a chemical indicator
G01N 33/543 - ImmunoassayBiospecific binding assayMaterials therefor with an insoluble carrier for immobilising immunochemicals
G01N 33/569 - ImmunoassayBiospecific binding assayMaterials therefor for microorganisms, e.g. protozoa, bacteria, viruses
43.
A COMPOSITE MATERIAL FOR REDUCING TEMPERATURE GAIN AND/OR INCREASING ATMOSPHERIC CONDENSATION ON A SURFACE OF A SUBSTRATE
The invention relates to a composite material for reducing temperature gain and/or for increasing atmospheric condensation on a surface of a substrate. The composite material may be used for passive cooling when exposed to the sky and/or is suitable for increasing atmospheric condensation on a surface of a substrate. In particular, the composite material when applied to a substrate (such as in the form of a single- or multi-layered coating) may be suitable for atmospheric water harvesting (AWH).
This disclosure generally relates to methods of processing an article comprising cellulosic fibres, for example waste paper, by subjecting the article to blunt force agitation and to composite materials derived from the processed articles. The composite materials find use as flame resistant materials or coatings, water storage materials and filtration materials.
D21B 1/10 - Fibrous raw materials or their mechanical treatment by dividing raw materials into small particles, e.g. fibres by dry methods the raw material being waste paperFibrous raw materials or their mechanical treatment by dividing raw materials into small particles, e.g. fibres by dry methods the raw material being rags by cutting actions
B01J 20/12 - Naturally occurring clays or bleaching earth
B01J 20/20 - Solid sorbent compositions or filter aid compositionsSorbents for chromatographyProcesses for preparing, regenerating or reactivating thereof comprising inorganic material comprising free carbonSolid sorbent compositions or filter aid compositionsSorbents for chromatographyProcesses for preparing, regenerating or reactivating thereof comprising inorganic material comprising carbon obtained by carbonising processes
C02F 1/28 - Treatment of water, waste water, or sewage by sorption
A method of manufacturing a patient-specific microfluidic device and a patient-specific microfluidic device are provided. The method includes obtaining three-dimensional (3D) information associated with vascular geometry in a region of interest from one or more clinical images associated with a patient, and fabricating the patient-specific microfluidic device using said 3D information. The patient-specific microfluidic device includes a flow channel having a geometry that substantially corresponds to the vascular geometry in the region of interest.
One aspect of the present disclosure relates to a method of quantifying soil carbon in a unit of land. The method generally comprises the steps of (i) obtaining an estimated spatial distribution of carbon content in the unit of land, (ii) stratifying the unit of land into a plurality of strata based at least partly on the spatial distribution of carbon content, (iii) selecting one or more locations from each of one or more of the plurality of strata, the one or more locations being selected with randomness, (iv) determining sample carbon content associated with the one or more first locations and (v) determining total carbon content in the unit of land based at least partly on the sample carbon content. In another aspect, this method may be used to quantify soil carbon sequestered in a unit of land by repeating steps (iv) and (v) at a second time and thereafter determining the amount of carbon sequestered. Furthermore, in quantifying the soil carbon sequestered, steps (ii) and (iii) may also be repeated at the second time after re-stratification of the unit of land based on sample carbon determined at the first time.
SOUTH EASTERN SYDNEY LOCAL HEALTH DISTRICT (Australia)
Inventor
You, Jingjing
Sutton, Gerard
Overmass, Morgan
Petsoglou, Constantinos
Hua, Sheng
Wen, Li
Abstract
The present invention relates to bioengineered collagen constructs and methods for the preparation and use of said constructs. The constructs and methods may find application in, but are not limited to, the provision of replacement tissue and/or cells, and/or the delivery of agents to biological targets such as tissues and cells. The constructs and methods may also find application in, but are not limited to, replacing endothelial tissue.
Disclosed is a face mask comprising a sterilisation chamber having an inner surface and configured such that gas inhaled and exhaled travels through the chamber when the mask is in use. The face mask comprises a UV-C light source, and a reflecting element on the inner surface of the chamber for reflecting UV-C light emitted from the UV-C light source such that gas travelling through the chamber is irradiated by the reflected UV-C light.
The present invention relates to the field of explosives. In particular, the present invention relates to explosive formulations for use or when used in reactive ground. The present invention also relates to uses of the explosive formulations and a method of blasting a reactive ground using the explosive formulations.
The present invention relates to the field of explosives. In particular, the present invention relates to explosive formulations for use or when used in reactive ground. The present invention also relates to uses of the explosive formulations and a method of blasting a reactive ground using the explosive formulations.
C06B 31/06 - Compositions containing an inorganic nitrogen-oxygen salt the salt being an alkali metal or an alkaline earth metal nitrate with carbon or sulfur with an organic non-explosive or an organic non-thermic component
C06B 47/14 - Compositions in which the components are separately stored until the moment of burning or explosion, e.g. "Sprengel"-type explosivesSuspensions of solid component in a normally non-explosive liquid phase, including a thickened aqueous phase comprising a solid component and an aqueous phase
The present invention is directed to a process for making a sprayable aqueous colloidal suspension, wherein the colloidal suspension comprises an interpenetrating polymer network and the interpenetrating polymer network comprises a polyurethane network and a polyacrylic network, the process comprising the steps: a) preparing a polyurethane prepolymer composition by mixing, at a reaction temperature between about 50 °C and about 120 °C: i. an aliphatic isocyanate having at least two isocyanate groups per molecule; ii. a diol; iii. a polyol having at least one acid group per molecule; and iv. a polyurethane polymerization catalyst; b) cooling the polyurethane prepolymer composition to a temperature less than the reaction temperature and then adding an alkyl amine to form a neutralized polyurethane prepolymer composition; then c) adding to the neutralized polyurethane prepolymer composition, with mixing: i. water; ii. a polyurethane chain extender, iii. A crosslinking acrylic monomer; and iv. a free radical initiator wherein a non-crosslinking acrylic monomer is also added in step b) or step c), to form the aqueous colloidal suspension.
C08G 18/12 - Prepolymer processes involving reaction of isocyanates or isothiocyanates with compounds having active hydrogen in a first reaction step using two or more compounds having active hydrogen in the first polymerisation step
The present invention relates to new pharmaceutical agents, and to their use in the treatment of proliferative diseases, such as cancer (in particular, brain cancer).
A differential detection system (1) has a light trapping diamond nitrogen vacancy doped layer (2) with an adjacent microwave resonator (4) having a resonance frequency with an operating bandwidth about the magnetic resonance of the nitrogen vacancy centre. The resonator (4) includes a suppressed portion (4B) and an unsuppressed portion (4A). A sensor photodiode (6A) is disposed distal the doped layer (2) and aligned with the unsuppressed portion (4A) of the microwave resonator (4), and a reference photodiode (6B) is spaced apart from and substantially in the same plane as the sensor photodiode (6A) and being aligned with the unsuppressed portion (4A) of the microwave resonator (4). The sensor (6A) and reference (6B) photodiodes are connected back-to-back to a single transimpedance amplifier.
G01R 33/032 - Measuring direction or magnitude of magnetic fields or magnetic flux using magneto-optic devices, e.g. Faraday
G01P 15/105 - Measuring accelerationMeasuring decelerationMeasuring shock, i.e. sudden change of acceleration by making use of inertia forces with conversion into electric or magnetic values by magnetically sensitive devices
Apparatus and methods for monitoring pregnancy or labour are disclosed. The example apparatus includes an electromyography (EMG) sensor having two or more EMG electrodes to monitor fetal or maternal activity during pregnancy or labour and one or more position sensors to monitor the relative positioning of the EMG electrodes during the fetal or maternal activity. The apparatus includes a monitoring device to be placed on a body and having a plurality of integrated sensors, the plurality of sensors including at least: a first sensor configured to detect a first type of signal from the body indicative of a first type of fetal or maternal activity during pregnancy or labour; and a second sensor configured to detect a second type of signal from the body, different from the first type of signal, also indicative of the first type of fetal or maternal activity during pregnancy or labour.
A ventilation assistance device and a method of using a ventilation assistance device for providing ventilation to a subject. The ventilation assistance device comprises a duct configured to be connectable between a source of gas and an interface device, for establishing fluid communication between the source of gas and the interface device for delivering gas to a subject's airway; a flow sensor configured to determine a flow volume of gas in the duct; and an operator interface configured to represent a measure of gas received by the subject by way of a plurality of indicators, each indicator being representative of the measure being within a particular range suitable for respective reference subjects having respective characteristics; wherein the operator interface is configured to display one of the plurality of indicators based on the flow volume determined by the flow sensor to represent to an operator the characteristic of the reference subject for which the gas received is suitable.
Encapsulated optoelectronic devices and methods of their fabrication are described. The encapsulation is based on the incorporation of a protective layer and a desiccant. Fabrication can be performed at low-temperature which minimises damage to the optoelectronic device and the encapsulation assists in preventing outgassing and device degradation. When encapsulated, the optoelectronic device demonstrates comparable performance to freshly fabricated devices and excellent long term stability.
The invention relates to compounds of formula (I), optionally radiolabelled with a radionuclide, and pharmaceutically acceptable salts, solvates, tautomers, N-oxides, stereoisomers and/or polymorphs thereof. Also disclosed are methods of using the compounds of formula (I) for detecting translocator protein (18 kDa) (TSPO). Further disclosed are methods of using the compounds of formula (I) for diagnosing and/or treating a disease, disorder or condition associated with TSPO.
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
An optical sensing system (1) has an optical input source (2) swept through a predetermined frequency range. A local RF signal driven (i) phase (5) or (ii) amplitude modulator (6) receive light from the input source (2) and produce an RF modulated light source feeding an optical waveguide (7) receiving the (i) phase or (ii) amplitude modulated light (B). An optical microresonator cavity (8) where modulated light (B) entering the optical waveguide (7) interacts with cavity (8) before exiting waveguide (7) to a photodetector (9) providing an electrical output signal corresponding to the photodetector optical input. An RF mixer (10) mixes the electrical output signal from the photodetector and the local RF signal to provide an electrical output signal (C) that is dependent of the amplitude and phase transmission information of the optical microresonator cavity (8).
G01M 11/00 - Testing of optical apparatusTesting structures by optical methods not otherwise provided for
G01N 21/77 - Systems in which material is subjected to a chemical reaction, the progress or the result of the reaction being investigated by observing the effect on a chemical indicator
G02B 6/122 - Basic optical elements, e.g. light-guiding paths
G02B 6/293 - Optical coupling means having data bus means, i.e. plural waveguides interconnected and providing an inherently bidirectional system by mixing and splitting signals with wavelength selective means
G02F 1/21 - Devices or arrangements for the control of the intensity, colour, phase, polarisation or direction of light arriving from an independent light source, e.g. switching, gating or modulatingNon-linear optics for the control of the intensity, phase, polarisation or colour by interference
The present invention relates to methods for promoting wound healing in a subject, comprising the administration of a β3-Adrenergic Receptor (β3AR) agonist to a subject in need thereof.
09 - Scientific and electric apparatus and instruments
Goods & Services
Air temperature sensors; instruments for scientific use in treatment of samples before analysis; apparatus controlled by computers for analysing samples; apparatus for recording humidity; apparatus for sampling the ambient atmosphere; apparatus for the identification of samples; electronic apparatus and instruments for the analysis of environmental contaminants (other than medical); electronic apparatus and instruments for the monitoring of environmental contaminants (other than medical); electronic equipment for testing environmental conditions; electronic equipment for measuring environmental conditions; electronic temperature monitors, other than for medical use; measurement devices; electronic temperature recorders, other than for medical use; apparatus for indicating measurements; electronic apparatus for measuring environmental conditions; measuring apparatus; apparatus for measuring humidity; humidity measuring apparatus; humidity measuring instruments; humidity meters; thermal energy measuring apparatus; humidity sensors; instruments for measuring wind; wind measurement apparatus; apparatus for measuring temperature (other than for medical purposes); measuring apparatus for temperature; devices for measuring wind speed; sensors for measuring wind speed; instruments for testing temperature (other than for medical use); temperature measurement instruments; sampling apparatus being laboratory apparatus; sampling apparatus being scientific apparatus; apparatus for measuring physiological stress (other than for medical purposes); physiological measuring apparatus, other than for medical use; physiological monitoring apparatus, other than for medical use; computer software; application software; data processing software; computer interfaces; computer interface devices.
62.
VANADIUM COMPOUNDS AND METHODS OF MAKING AND USING THEREOF
Disclosed are vanadium (V) compounds and pharmaceutical compositions comprising these vanadium compounds. Also disclosed are methods of making and using these vanadium compounds, for example, to treat cancer (e.g., including brain cancer).
The present disclosure relates to a composite coagulant, the composite coagulant comprising one or more particulate materials, wherein the one or more particulate materials is at least partially coated with one or more ionic polymers, and wherein the one or more particulate materials are insoluble or sparingly soluble in water. The present disclosure also provides a method of making the composite coagulant and a method of treating wastewater using the composite coagulant.
C08L 33/02 - Homopolymers or copolymers of acidsMetal or ammonium salts thereof
C08L 39/00 - Compositions of homopolymers or copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by a single or double bond to nitrogen or by a heterocyclic ring containing nitrogenCompositions of derivatives of such polymers
The present invention relates to the field of medical diagnostics, prognosis and monitoring treatment efficacy. In particular, it relates to methods and kits for predicting the risk of, or diagnosing, coronary artery disease (CAD).
WESTMEAD INSTITUTE OF MEDICAL RESEARCH (Australia)
WESTERN SYDNEY LOCAL HEALTH DISTRICT (Australia)
VICTOR CHANG CARDIAC RESEARCH INSTITUTE (Australia)
Inventor
Chong, James
Mckinna, Emily
Payne, Richard
Ford, Daniel
Harvey, Richard
Contreras, Osvaldo
Abstract
Disclosed herein are compounds of formula (I) wherein X, L1, and HSA conjugate are as defined herein., methods of preparation thereof, and methods of using thereof for improving cardiac repair, particularly post infarct.
A61K 47/64 - Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
A61P 9/00 - Drugs for disorders of the cardiovascular system
C07K 7/06 - Linear peptides containing only normal peptide links having 5 to 11 amino acids
66.
A PRO-MOIETY FOR FORMING A PRODRUG SELECTIVELY CLEAVED BY PROSTATE-SPECIFIC ANTIGEN (PSA)
A pro-moiety and a composition comprising a pro-moiety for use in a therapeutically or diagnostically effective amount in a method for detecting and/or treating prostate cancer in a subject is disclosed. The pro-moiety comprises a first peptide, and a second peptide that is linked to the first peptide, wherein the peptide comprises a sequence that is configured near a first terminus for conjugating to a drug to form a prodrug that is rapidly and/or highly selectively cleaved by prostate-specific antigen (PSA), and configured at a second terminus to bind with high selectivity to the active site of PSA, and the second peptide comprises a sequence having a negative charge to slow uptake of the prodrug by cells, and wherein the second peptide is cleaved from the first peptide upon proteolysis by PSA to produce a conjugate of the first peptide and the drug that is suitable for uptake by target cells.
C07K 7/06 - Linear peptides containing only normal peptide links having 5 to 11 amino acids
A61K 47/64 - Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
The present invention provides methods and kits for the determination of oxidative status and/or the detection of myeloperoxidase in a faecal sample. The methods and kits may find application in diagnosing and/or determining the severity of inflammatory bowel disease (IBD) and/or infectious colitis.
A method of reducing a gaseous compound, for example, nitrogen or carbon dioxide, the method comprising the steps of subjecting the gaseous compound to plasma forming conditions to form a plasma; contacting the plasma with water or an electrolyte at a plasma-water or electrolyte-water interface, thereby to provide a dissolved plasma derived species; and electrocatalytically reducing said dissolved plasma derived species to provide a reduced compound. The plasma may for example be generated by a combination of glow discharge and spark discharge in a configuration of a pin-to-liquid with no enclosure, pin-to-liquid with nozzle enclosure, or a pin-to-liquid with a column bubbler enclosure. A catalyst, such as transition metal, maybe added, advantageously in the form of a nano structured catalyst.
C25B 11/075 - Electrodes formed of electrocatalysts on a substrate or carrier characterised by the electrocatalysts material consisting of a single catalytic element or catalytic compound
SOUTH EASTERN SYDNEY LOCAL HEALTH DISTRICT (Australia)
THE UNIVERSITY OF WOLLONGONG (Australia)
Inventor
You, Jingjing
Sutton, Gerard
Overmass, Morgan
Lovicu, Frank
Wallace, Gordon
Abstract
The present invention relates to compositions suitable for the delivery of agents to biological targets such as tissues and cells and/or capable of promoting the growth and/or proliferation of cells, and methods for the production thereof. Specifically, a printable collagen bioink comprising type IV collagen is used to produce crosslinked collagen gels comprising mammalian cells, such as endothelial or epithelial cells, for corneal regeneration.
09 - Scientific and electric apparatus and instruments
Goods & Services
Air temperature sensors; instruments for scientific use in
treatment of samples before analysis; apparatus controlled
by computers for analysing samples; apparatus for recording
humidity; apparatus for sampling the ambient atmosphere;
apparatus for the identification of samples; electronic
apparatus and instruments for the analysis of environmental
contaminants (other than medical); electronic apparatus and
instruments for the monitoring of environmental contaminants
(other than medical); electronic equipment for testing
environmental conditions; electronic equipment for measuring
environmental conditions; electronic temperature monitors,
other than for medical use; measurement devices; electronic
temperature recorders, other than for medical use; apparatus
for indicating measurements; electronic apparatus for
measuring environmental conditions; measuring apparatus;
apparatus for measuring humidity; humidity measuring
apparatus; humidity measuring instruments; humidity meters;
thermal energy measuring apparatus; humidity sensors;
instruments for measuring wind; wind measurement apparatus;
apparatus for measuring temperature (other than for medical
purposes); measuring apparatus for temperature; devices for
measuring wind speed; sensors for measuring wind speed;
instruments for testing temperature (other than for medical
use); temperature measurement instruments; sampling
apparatus being laboratory apparatus; sampling apparatus
being scientific apparatus; apparatus for measuring
physiological stress (other than for medical purposes);
physiological measuring apparatus, other than for medical
use; physiological monitoring apparatus, other than for
medical use; computer software; application software; data
processing software; computer interfaces; computer interface
devices.
A process for controlling the produc on of urease by biofilm forming bacteria by treatment with N- acetyl cysteine (NAC). A process of preven ng catheter bacterial encrusta on by treatment with NAC. A process of inhibi ng the urease secreted by P. mirabilis isolates by treatment with NAC. A process of inhibi ng bacterial migra on through catheter segments by treatment with NAC. A process of reducing the elemental profile of a catheter biofilm by treatment with NAC. A process of reducing the inflammatory response of cells to urease by treatment with NAC. A process of reducing the level of bladder epithelial cell invasion by treatment with NAC. The NAC may be used alone or in combina on with one or more an bio cs and/or as a formula on.
The present invention relates to a compound of formula (I): or a salt or solvate thereof, combinations comprising same, uses and methods thereof, and kits comprising same.
The present invention relates to a compound of formula (I): or a salt or solvate thereof, combinations comprising same, uses and methods thereof, and kits comprising same.
CENTENARY INSTITUTE OF CANCER MEDICINE AND CELL BIOLOGY (Australia)
UNIVERSITY OF SYDNEY (Australia)
Inventor
Hogg, Philip
Ho Shon, Ivan
Abstract
The invention relates to compounds according to Formula (I):
1-5 straight or branched alkyl group; and Z is a radioisotope with a half-life of less than 4 days, or a pharmaceutically acceptable salt, ester, prodrug or solvate thereof, uses of said compounds, and methods of preparing said compounds. The invention also relates to diagnostic methods utilizing said compounds.
An apparatus (200) for shielding a sensor, the sensor being configured to measure one or more meteorological parameters, the apparatus (200) including: a first shielding element (202) to be irradiated by sunlight, the first shielding element (202) having a hollow body (204) providing a longitudinal central axis (208), the body (204) at least partly surrounding a chamber (206) in which the sensor is to be located; a second shielding element (212) axially spaced from an upper portion of the body (204) to form an air opening between the first and second shielding elements (202, 212) to permit air to pass from the chamber (206) and across the body (204); the apparatus (200) further including an airflow generator (214) positioned within the chamber (206) and operatively associated with the first and second shielding elements (202, 212) to provide an airflow between the opening and the chamber (206).
H05K 7/20 - Modifications to facilitate cooling, ventilating, or heating
G01W 1/02 - Instruments for indicating weather conditions by measuring two or more variables, e.g. humidity, pressure, temperature, cloud cover or wind speed
75.
SIGNAL STRENGTH PREDICTION IN COMPLEX ENVIRONMENTS
Disclosed herein are systems and methods for estimating signal strength of wireless communications in different environments, wherein the method may comprise cropping an image of a terrain environment into multiple image units, wherein the image includes a base station point and a measurement point; identifying environmental features, via a convolutional neural network (CNN), wherein the multiple image units are used as inputs to the CNN; applying at least one Long Short-Term Memory (LSTM) neural network, to the identified environmental features, to model a signal propagation pattern in the terrain environment; concatenating a final hidden state output of the LSTM neural network with additional communication features to produce vectors; and inputting the vectors into a deep neural network (DNN) to establish a signal strength prediction model.
G06N 3/0442 - Recurrent networks, e.g. Hopfield networks characterised by memory or gating, e.g. long short-term memory [LSTM] or gated recurrent units [GRU]
G06N 3/084 - Backpropagation, e.g. using gradient descent
G06V 10/26 - Segmentation of patterns in the image fieldCutting or merging of image elements to establish the pattern region, e.g. clustering-based techniquesDetection of occlusion
The invention relates to the treatment of thromboembolic conditions, to fibrin clot formation and related thrombin activity, and to preparation of compounds, in particular, peptides and polypeptides for inhibiting, or for modifying the cleavage of fibrinogen by thrombin.
09 - Scientific and electric apparatus and instruments
Goods & Services
(1) Air temperature sensors; instruments for scientific use in treatment of samples before analysis; apparatus controlled by computers for analysing samples; apparatus for recording humidity; apparatus for sampling the ambient atmosphere; apparatus for the identification of samples; electronic apparatus and instruments for the analysis of environmental contaminants (other than medical); electronic apparatus and instruments for the monitoring of environmental contaminants (other than medical); electronic equipment for testing environmental conditions; electronic equipment for measuring environmental conditions; electronic temperature monitors, other than for medical use; measurement devices; electronic temperature recorders, other than for medical use; apparatus for indicating measurements; electronic apparatus for measuring environmental conditions; measuring apparatus; apparatus for measuring humidity; humidity measuring apparatus; humidity measuring instruments; humidity meters; thermal energy measuring apparatus; humidity sensors; instruments for measuring wind; wind measurement apparatus; apparatus for measuring temperature (other than for medical purposes); measuring apparatus for temperature; devices for measuring wind speed; sensors for measuring wind speed; instruments for testing temperature (other than for medical use); temperature measurement instruments; sampling apparatus being laboratory apparatus; sampling apparatus being scientific apparatus; apparatus for measuring physiological stress (other than for medical purposes); physiological measuring apparatus, other than for medical use; physiological monitoring apparatus, other than for medical use; computer software for environmental analysis and heat stress management; application software for environmental analysis and heat stress management; data processing software for environmental analysis and heat stress management; computer interfaces for environmental analysis and heat stress management; computer interface devices.
09 - Scientific and electric apparatus and instruments
Goods & Services
Air temperature sensors; instruments for scientific use in treatment of air samples before analysis; apparatus controlled by computers for analysing air samples; apparatus for recording humidity; apparatus for sampling the ambient atmosphere; apparatus for the identification of air samples; electronic apparatus and instruments for the analysis of environmental contaminants, other than for medical use; electronic apparatus and instruments for the monitoring of environmental contaminants, other than for medical use; electronic equipment for testing environmental conditions; electronic equipment for measuring environmental conditions; electronic temperature monitors, other than for medical use; electronic measurement devices for measuring environmental conditions, namely temperature, wind direction and intensity, humidity, radiation and airborne particle sizes; electronic temperature recorders, other than for medical use; apparatus for indicating measurements of environmental conditions, namely temperature, wind direction and intensity, humidity, radiation and airborne particle sizes; electronic apparatus for measuring environmental conditions; measuring apparatus for temperature and humidity levels in gases and solid substances; apparatus for measuring humidity; humidity measuring apparatus; humidity measuring instruments; humidity measuring meters; thermal energy measuring apparatus; humidity measuring sensors; instruments for measuring wind direction and intensity; wind intensity measurement apparatus; apparatus for measuring temperature, other than for medical purposes; measuring apparatus for temperature; devices for measuring wind speed; sensors for measuring wind speed; instruments for testing temperature, other than for medical use; temperature measurement instruments; temperature sampling apparatus being a laboratory apparatus; temperature sampling apparatus being a scientific apparatus; apparatus for measuring physiological stress, other than for medical purposes; physiological data measuring apparatus, other than for medical use; physiological monitoring apparatus, other than for medical use; downloadable computer software for environmental analysis and heat stress management; downloadable application software for environmental analysis and heat stress management; downloadable data processing software for environmental analysis and heat stress management; computer interfaces for environmental analysis and heat stress management; computer interface devices
79.
THERAPEUTIC RADIOLABELLED CONJUGATES AND THEIR USE IN THERAPY
CENTENARY INSTITUTE OF CANCER MEDICINE AND CELL BIOLOGY (Australia)
UNIVERSITY OF SYDNEY (Australia)
Inventor
Hogg, Philip
Ho Shon, Ivan
Abstract
The invention relates to compounds according to Formula (I) wherein A is —As(OH)2 or an arsenoxide equivalent group; each of R1, R2, R3 and R4 is independently selected from H, X, OH, NH2, CO, SCN, —CH2NH, —NHCOCH3, —NHCOCH2X or NO, and X is a halogen; R5 is —NHCH2COOH, OH or OR6, wherein R6 is a C1-5 straight or branched alkyl group; and Z is a therapeutic radioisotope, or a pharmaceutically acceptable salt, ester, prodrug or solvate thereof, uses of said compounds, and methods of preparing said compounds. The invention also relates to therapeutic methods utilizing said compounds. The invention further relates to processes for preparing compounds according to Formula (I) wherein Z is a radioisotope.
The invention relates to compounds according to Formula (I) wherein A is —As(OH)2 or an arsenoxide equivalent group; each of R1, R2, R3 and R4 is independently selected from H, X, OH, NH2, CO, SCN, —CH2NH, —NHCOCH3, —NHCOCH2X or NO, and X is a halogen; R5 is —NHCH2COOH, OH or OR6, wherein R6 is a C1-5 straight or branched alkyl group; and Z is a therapeutic radioisotope, or a pharmaceutically acceptable salt, ester, prodrug or solvate thereof, uses of said compounds, and methods of preparing said compounds. The invention also relates to therapeutic methods utilizing said compounds. The invention further relates to processes for preparing compounds according to Formula (I) wherein Z is a radioisotope.
THE WESTMEAD INSTITUTE FOR MEDICAL RESEARCH (Australia)
Inventor
Chong, James
Clayton, Zoe
Selvakumar, Dinesh
George, Jacob
Reyes, Leila
Abstract
Disclosed herein is a method of identifying an arrhythmogenic pluripotent stem cell-derived cardiomyocyte (PSC-CM), the method comprising: (i) determining whether CD200 is expressed on a surface of the PSC-CM; wherein if CD200 is expressed on the surface of the PSC-CM, the PSC-CM is an arrhythmogenic PSC-CM.
C12N 5/077 - Mesenchymal cells, e.g. bone cells, cartilage cells, marrow stromal cells, fat cells or muscle cells
A61K 31/343 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
A61K 31/55 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
The present invention relates to materials and methods for creating and maintaining a cereal plant line for the production of a hybrid cereal plant, that include for example, and not limitation, using the BLue Aleurone (BLA) system.
A system and method of detecting presence of arrythmia in an electrocardiogram (ECG) signal. The method comprises steps of applying a decomposition algorithm to one or more portions of the ECG signal, each portion corresponding to at least one heartbeat. The method also comprises, for each portion, selecting at least one output of the decomposition algorithm; providing the selected at least one output to a first trained convolutional neural network (CNN) arrangement, the first CNN arrangement generating coefficients of a predetermined size; and inputting the coefficients of the predetermined size to a second trained CNN arrangement, the second CNN arrangement trained to output a classification of whether arrythmia is present in the portion of the ECG.
G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
A61B 5/00 - Measuring for diagnostic purposes Identification of persons
A61B 5/352 - Detecting R peaks, e.g. for synchronising diagnostic apparatusEstimating R-R interval
A photonic phase shifter for controlling a phase shift of an input optical signal, the photonic phase shifter comprising: an optical circuit formed on an electo-optic layer, the optical circuit comprising: an input port for receiving the input optical signal, an output port for sending an output signal, and a microring resonator comprising an optical microring and an optical waveguide; an electrical circuit formed on a dielectric layer, the electrical circuit comprising: at least two RF electrodes for receiving an input electrical signal, a resonant loop, and a capacitive electrode, wherein the RF electrodes are in electrical communication with the capacitive electrode via the resonant loop; wherein the electrical circuit is positioned relative to the optical circuit to enable the capacitive electrode to interact with the microring resonator based on the input electrical signal.
H03H 7/21 - Networks for phase shifting providing two or more phase shifted output signals, e.g. n-phase output
G02B 6/12 - Light guidesStructural details of arrangements comprising light guides and other optical elements, e.g. couplings of the optical waveguide type of the integrated circuit kind
G02F 1/01 - Devices or arrangements for the control of the intensity, colour, phase, polarisation or direction of light arriving from an independent light source, e.g. switching, gating or modulatingNon-linear optics for the control of the intensity, phase, polarisation or colour
An optical sensor for detecting a chemical species in a sample, the optical sensor comprising a single mode fibre having a fibre Bragg grating, wherein the fibre Bragg grating has a refractive index profile, the optical sensor arranged to provide an output optical signal based on a positive detection of the chemical species in the sample, wherein the sample, upon illumination, emits a sample optical signal having an optical frequency signature comprising a plurality of spectral lines that are associated with the chemical species, wherein the refractive index profile is associated with the optical frequency signature, and the fibre Bragg grating is arranged to be modulated to generate the output optical signal.
G01N 21/63 - Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light optically excited
G01N 21/17 - Systems in which incident light is modified in accordance with the properties of the material investigated
B01J 8/02 - Chemical or physical processes in general, conducted in the presence of fluids and solid particlesApparatus for such processes with stationary particles, e.g. in fixed beds
B01J 8/08 - Chemical or physical processes in general, conducted in the presence of fluids and solid particlesApparatus for such processes with moving particles
B01J 19/08 - Processes employing the direct application of electric or wave energy, or particle radiationApparatus therefor
The present invention relates to nanoparticle bioconjugates comprising binding proteins for binding to a cancer cell and an antigen of an immune cell, and uses and methods of treatment comprising administration thereof.
A61K 39/00 - Medicinal preparations containing antigens or antibodies
A61K 47/50 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
A61K 47/69 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
C07K 16/32 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products from oncogenes
Substrates modified with plasma-activated coatings are provided, as are processes for their preparation. The coated substrates may possess high transparency and are radical rich, enabling covalent attachment of biomolecules, for example proteins.
A composite all optical-fibre based tapered photonic waveguide (110) including a single or multiple secondary waveguides (120) within or around a primary waveguide (118) is described. The composite optical fibre may also be termed a beam tailoring optical fibre (BT Fibre) (110). In use, at thelarger secondary end (114) both the primary waveguide (118) and the secondary waveguide/s (120) may guide modes at a particular wavelength. However, at the same wavelength, adiabatically tapering down the waveguides (118, 120) reduces the dimensions of the secondary waveguide/s (120) such that all the secondary waveguide/s (120) become effectively non-guiding at the smaller primary end (112), whilst the primary waveguide (118) still guides. In other words, the composite optical fibre is a spatially modulating optical fibre (110).
The present invention is directed to a probe for detecting a transition metal, the probe comprising: a metal chelating portion configured to coordinate with a transition metal; a label portion configured to be detectable; and a linker bound to both the metal chelating portion and the label portion, wherein the linker is configured to react with a nucleophile when the metal chelating portion coordinates with the transition metal, as well in vivo and in vitro methods and uses thereof.
A61B 5/00 - Measuring for diagnostic purposes Identification of persons
A61B 5/055 - Detecting, measuring or recording for diagnosis by means of electric currents or magnetic fieldsMeasuring using microwaves or radio waves involving electronic [EMR] or nuclear [NMR] magnetic resonance, e.g. magnetic resonance imaging
A61B 90/00 - Instruments, implements or accessories specially adapted for surgery or diagnosis and not covered by any of the groups , e.g. for luxation treatment or for protecting wound edges
C07D 401/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
Disclosed is a computer implemented method, system and computer readable medium for performing blockchain-based identity management for a supply chain of a computerised network. In one aspect, the method includes receiving, by a computerised device of a party, an identity issuing transaction initiated by a computerised component or service being in the supply chain, the identity issuing transaction being indicative of a name of the computerised component or service, an identity issuing request message, and a first random number obtained from a distributed database, wherein the identity issuing transaction is initiated by the computerised component or service in response to determining the party is an authoritative party recorded in the blockchain and permitted to issue an identity, invoking a first smart contract, and executing an identity issuance logic of the first smart contract.
G06Q 20/40 - Authorisation, e.g. identification of payer or payee, verification of customer or shop credentialsReview and approval of payers, e.g. check of credit lines or negative lists
G06Q 20/30 - Payment architectures, schemes or protocols characterised by the use of specific devices
H04L 9/32 - Arrangements for secret or secure communicationsNetwork security protocols including means for verifying the identity or authority of a user of the system
H04L 9/00 - Arrangements for secret or secure communicationsNetwork security protocols
H04L 9/30 - Public key, i.e. encryption algorithm being computationally infeasible to invert and users' encryption keys not requiring secrecy
One aspect of the present disclosure relates to a method of quantifying soil carbon in a unit of land. The method generally comprises the steps of (i) obtaining an estimated spatial distribution of carbon content in the unit of land, (ii) stratifying the unit of land into a plurality of strata based at least partly on the spatial distribution of carbon content, (iii) selecting one or more locations from each of one or more of the plurality of strata, the one or more locations being selected with randomness, (iv) determining sample carbon content associated with the one or more first locations and (v) determining total carbon content in the unit of land based at least partly on the sample carbon content. In another aspect, this method may be used to quantify soil carbon sequestered in a unit of land by repeating steps (iv) and (v) at a second time and thereafter determining the amount of carbon sequestered. Furthermore, in quantifying the soil carbon sequestered, steps (ii) and (iii) may also be repeated at the second time after re-stratification of the unit of land based on sample carbon determined at the first time.
The invention provides a system for pumping a fluid through a target unit, comprising a source of compressed gas, a gas circuit connected to said source of compressed gas and including gas flow control apparatus, a first connection and a second connection for connecting to, respectively, afferent and efferent ends of the target unit, a fluid flow circuit in fluid communication with said first and second connections, the fluid flow circuit including fluid control apparatus and a first and second fluid reservoir, wherein the gas flow control apparatus provides coordinated delivery and release of compressed gas to dynamically control fluid level in each of said first and second fluid reservoirs in order to provide, by way of operation of the fluid control apparatus in the fluid flow circuit, continuous fluid flow through the target unit in a single direction in accordance with a predetermined flow profile.
Systems, methods, and apparatus are disclosed for cardiac structure tracking. An example method includes segmenting a diaphragm or respiratory surrogate, heart, and target. The method also includes performing a peak-exhale to peak-inhale registration and generating a respiratory motion model. The method further includes tracking the diaphragm using X-ray imaging and estimating a target position for an x-ray guided cardiac radioablation treatment. The example method provides directly, precisely controlled x-ray guided cardiac radioablation that accurately targets the substrates of cardiac ablation while minimizing doses to healthy tissue.
The present application relates to radio detection and ranging (radar) systems and, in particular, to a radar system having a photonics-based signal generator. Such a radar system comprises a stepped-frequency optical signal generator, an optical-to-electrical converter, and a transmitter. The stepped-frequency optical signal generator is configured for converting an optical signal into a stepped-frequency optical signal. The optical-to-electrical converter for converting the stepped-frequency optical signal into a stepped-frequency electrical signal. The transmitter for transmitting a microwave signal based on the stepped-frequency electrical signal.
A61B 5/0507 - Detecting, measuring or recording for diagnosis by means of electric currents or magnetic fieldsMeasuring using microwaves or radio waves using microwaves or terahertz waves
95.
VOLUMETRIC ABSORPTIVE MICROSAMPLING DEVICES AND METHODS OF USING THE SAME
The object of the present invention is to provide a microsampling device that allows analysis of proteins in a biological sample, such as a whole blood sample, and provide methods of using the same.
The present invention relates to a recycling process for a laminate and a solution used in such a process. The present invention finds particular application in the removal of an adhered overlay from an underlying substrate material such as plastic. The process includes subjecting the laminate to an impact frictional striking force, thereby substantially separating the substrate layer from the one or more surface layers of the overlay and then washing the substrate layer with a washing solution to remove the remaining surface layers of the overlay and glue from the substrate layer. The washing solution may be an aqueous solution including a surfactant, a solvent and a base.
B08B 7/02 - Cleaning by methods not provided for in a single other subclass or a single group in this subclass by distortion, beating, or vibration of the surface to be cleaned
B08B 3/08 - Cleaning involving contact with liquid the liquid having chemical or dissolving effect
B08B 7/04 - Cleaning by methods not provided for in a single other subclass or a single group in this subclass by a combination of operations
B08B 5/02 - Cleaning by the force of jets, e.g. blowing-out cavities
B08B 5/04 - Cleaning by suction, with or without auxiliary action
Methods, apparatuses and systems are disclosed for dose-based optimization related to multi-target multi-leaf collimator ("MLC") tracking during radiation therapy. In an example, a method includes calculating a planned radiation dose volume using an MLC plan and assigning dose voxels from the planned radiation dose volume to two or more patient tissue targets. The method also includes shifting the dose voxels such that the dose voxels that are assigned to one of the patient tissue targets are shifted according to motion of the respective patient tissue target, and integrating a delivered three-dimensional dose into a two-dimensional beam's eye view ("BEV") grid for each of the dose voxels. The method further includes fitting, for each leaf track, an MLC aperture by minimizing a cost function, accumulating a delivered dose based on the fitted leaf positions, and updating a gantry position and MLC leaf positions to update a next planned dose.
G16H 20/40 - ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to mechanical, radiation or invasive therapies, e.g. surgery, laser therapy, dialysis or acupuncture
A system and method for measuring acceleration. The system comprises a diamond having a nitrogen-vacancy centre configured to emit fluorescence under optical illumination in presence of a radio frequency field tuned to a resonant frequency of the nitrogen-vacancy centre, and a magnet, wherein a distance between the magnet and the diamond varies in response to acceleration of the system, the change in distance altering a magnetic field experienced by the diamond. The system also comprises an optical sensor, the optical sensor configured to sense variation in fluorescence emitted by the diamond in response to the altered magnetic field for measuring acceleration.
G01P 15/105 - Measuring accelerationMeasuring decelerationMeasuring shock, i.e. sudden change of acceleration by making use of inertia forces with conversion into electric or magnetic values by magnetically sensitive devices
G01P 15/08 - Measuring accelerationMeasuring decelerationMeasuring shock, i.e. sudden change of acceleration by making use of inertia forces with conversion into electric or magnetic values
G01P 15/093 - Measuring accelerationMeasuring decelerationMeasuring shock, i.e. sudden change of acceleration by making use of inertia forces with conversion into electric or magnetic values by photoelectric pick-up
G01P 15/18 - Measuring accelerationMeasuring decelerationMeasuring shock, i.e. sudden change of acceleration in two or more dimensions
G01R 33/032 - Measuring direction or magnitude of magnetic fields or magnetic flux using magneto-optic devices, e.g. Faraday
G01V 7/04 - Electric, photoelectric, or magnetic indicating or recording means
H10N 97/00 - Electric solid-state thin-film or thick-film devices, not otherwise provided for
99.
Dose-based optimization for multi-leaf collimator (“MLC”) tracking during radiation therapy methods and apparatus
Methods, apparatuses and systems are disclosed for dose-based optimization related to multi-leaf collimator (“MLC”) tracking during radiation therapy. In an example, a method includes calculating a planned radiation dose using an MLC plan in an un-shifted dose volume, acquiring, using a radiation machine, a target position through motion tracking, and shifting the dose volume by the target position. The method also includes integrating a three-dimensional dose into a two-dimensional beam's eye view grid and fitting, using the radiation machine for each leaf track, an MLC aperture by minimizing a cost function. The method further includes calculating and accumulating a delivered dose based on the fitted leaf positions of the MLC and updating a gantry position and MLC leaves to update a next planned dose.
Systems and methods for received signal strength (RSS) prediction using a distributed federated learning framework are disclosed herein. In an example, a system for predicting RSS includes a plurality of user devices. Each of the user devices is configured to generate private information including at least one of user device movement trajectories, user device velocities, or RSS measurements at a plurality of locations over time. The system also includes a server configured to store, retrieve, or access public information that is related to a serving base station for each user device of the plurality of user devices. The server uses a distributed machine learning process in conjunction with the public and private information to accurately predict the RSS of the plurality of the user devices at locations that each of the user devices has not yet reached without revealing the private information of each user device.
